Clinical Trial: Ibrutinib with Pomalidomide and Dexamethasone for Relapsed/Refractory Myeloma Patients
A Phase I clinical trial will study a new drug called ibrutinib in combination with pomalidomide (an immunomodulator) and dexamathasone (a steroid.)
The Phase II study will be divided into two groups for relapsed/refractory myeloma patients:
There are 5 locations for this trial.
To find the clinical trial on SparkCures, click here:
Ibrutinib/Pom/Dex Clinical Trial